Market Newsdesk

NASDAQ:EU

TSXV:EU



www.encoreuranium.com

DALLAS
, Sept. 2, 2025 /PRNewswire/ – enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the “Company” or “enCore”), America’s Clean Energy Company™, announced today that its Dewey Burdock ISR Uranium Project (“Dewey Burdock Project”), located in South Dakota, has been approved for inclusion in the Fast-41 Program by the U.S. Federal Permitting Improvement Steering Council (“Permitting Council”). This is a component of the implementation of President Trump’s Executive Order on Immediate Measures to Increase American Mineral Production. The Company’s Dewey Burdock Project received its Source and Byproduct Materials License in 2014, from the Nuclear Regulatory Commission (“NRC”), now under timely renewal, and will work with the NRC as the lead agency for federal permitting. enCore’s objective is to advance the Dewey Burdock Project into development and operation utilizing the In-Situ Recovery (“ISR”) uranium extraction process.

Under the Executive Order, the Permitting Council identifies priority infrastructure and critical mineral projects to receive accelerated permitting review. The addition of the first South Dakota ISR project supports the domestic uranium production focus of the United States. This focus enables the development of essential clean energy, extracted through environmentally responsible ISR technology, to provide affordable, reliable domestic energy. To learn more, please visit the Federal Permitting Dashboard: Dewey Burdock ISR Uranium Project | Permitting Dashboard

Executive Chairman, William M. Sheriff, stated: “enCore Energy is honored to see the Dewey Burdock Uranium Project selected as a Fast-41 Project and we look forward to working with the Permitting Council and the NRC to advance the project in an open and transparent process. Dewey Burdock plays an important role in supporting the U.S. nuclear fuel supply chain with domestically produced uranium for many years into the future. As the first critical mineral extraction project selected within the State of South Dakota we also look to working with the state government, tribal governments and local communities as we focus on building a stronger domestic supply of clean and affordable energy and providing economic stimulus to southwest South Dakota.”

About the Dewey Burdock ISR Uranium Project

The Dewey Burdock ISR Uranium Project (“Dewey Burdock Project), wholly owned by enCore, is an advanced-stage uranium project located in Custer and Fall River counties in South Dakota. The Dewey Burdock Project will recover uranium from subsurface sandstone ore bodies through ISR technology, which utilizes a chemical-free water based solution in the production wellfield to dissolve uranium minerals in place and then pumps the uranium-bearing solution to a central processing plant for recovery. The use of ISR technology allows for minimal surface disturbance compared to conventional open-pit or underground uranium mining. The project consists of wellfield areas, a central processing plant, supporting infrastructure and environmental protection systems.

The Company’s Dewey Burdock Project received its Source and Byproduct Materials License SUA-1600 on April 8, 2014, from the NRC, covering 10,580 acres. The Company controls the mineral and surface rights for the area pertaining to the NRC license. With the approval of Fast-41, enCore’s objective is to advance the Dewey Burdock Project into development and operation as an ISR uranium extraction project.

Mineral Resource Summary

John M. Seeley, Ph.D., P.G., C.P.G., enCore’s Chief Geologist, and a Qualified Person under Canadian National Instrument 43-101 and S-K 1300, has reviewed and approved the technical disclosure in this news release on behalf of the Company.

About the Permitting Council and FAST-41

Established in 2015 by Title 41 of the Fixing America’s Surface Transportation Act (FAST-41), the Permitting Council, is a federal agency charged with improving the transparency and predictability of the federal environmental review and authorization process for certain critical infrastructure projects. The Permitting Council is comprised of the Permitting Council Executive Director, who serves as the Council Chair; 13 federal agency Council members (including deputy secretary-level designees of the Secretaries of Agriculture, Army, Commerce, Interior, Energy, Transportation, Defense, Homeland Security, and Housing and Urban Development, the Administrator of the Environmental Protection Agency, and the Chairs of the Federal Energy Regulatory Commission, Nuclear Regulatory Commission, and the Advisory Council on Historic Preservation); and the Chair of the White House Council on Environmental Quality and the Director of the Office of Management and Budget.

The Permitting Council coordinates federal environmental reviews and authorizations for projects that seek and qualify for FAST-41 coverage. FAST-41 covered projects are entitled to comprehensive permitting timetables and transparent, collaborative management of those timetables on the Federal Permitting Dashboard.

About enCore Energy Corp.

enCore Energy Corp., America’s Clean Energy Company™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple Central Processing Plants in operation. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy.

Following upon enCore’s demonstrated success in South Texas, future projects in enCore’s planned project pipeline include the Dewey Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.

www.encoreuranium.com
 

Cautionary Note Regarding Forward Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements and information that are not statements of historical fact include, but are not limited to, any information relating to statements regarding future or potential extraction, and any other statements regarding future expectations, beliefs, goals or prospects, statements regarding the success of current and future ISR operations, our development plans, including that participation in the FAST-41 Program will accelerate the permitting process on the Dewey Burdock Project and that required permits will be received timely, the anticipated and assumed permitting and licensing timelines of the Dewey Burdock Project, the anticipated construction timelines and projects for the Dewey Burdock Project, our future extraction plans and expectations, including costs, extraction amounts, flow capacity and processing amounts of uranium for the Project and our commitment to working with local communities and indigenous governments to create positive impact from corporate developments should be considered forward looking statements. All such forward-looking statements are not guarantees of future results and forward-looking statements are subject to important risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that could cause actual results to differ materially from those expressed in any forward looking statement, including those described in greater detail in our filings with the SEC and on SEDAR+, particularly those described in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, annual information form and MD&A. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with assumptions regarding project economics; discount rates; expenditures and the current cost environment; timing and schedule of the projects, general economic conditions; adverse industry events; future legislative and regulatory developments; the ability of enCore to implement its business strategies; receipt of permitting and regulatory approvals on a timely basis and other risks. A number of important factors could cause actual results or events to differ materially from those indicated or implied by such forward-looking statements, including without limitation exploration and development risks, changes in commodity prices, access to skilled personnel, the results of exploration and development activities; extraction risks; uninsured risks; regulatory risks; defects in title; the availability of materials and equipment, timeliness of government approvals and unanticipated environmental impacts on operations; litigation risks; risks posed by the economic and political environments in which the Company operates and intends to operate; increased competition; assumptions regarding market trends and the expected demand and desires for the Company’s products and proposed products; reliance on industry equipment manufacturers, suppliers and others; the failure to adequately protect intellectual property; the failure to adequately manage future growth; adverse market conditions, the failure to satisfy ongoing regulatory requirements and factors relating to forward looking statements listed above. Should one or more of these risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. The Company assumes no obligation to update the information in this communication, except as required by law. Additional information identifying risks and uncertainties is contained in filings by the Company with the various securities commissions which are available online at www.sec.gov and www.sedarplus.ca.

Forward-looking statements are provided for the purpose of providing information about the current expectations, beliefs and plans of management. Such statements may not be appropriate for other purposes and readers should not place undue reliance on these forward-looking statements, that speak only as of the date hereof, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

View original content to download multimedia:https://www.prnewswire.com/news-releases/encore-energy-corp-announces-the-dewey-burdock-isr-uranium-project-approved-for-united-states-government-fast-track-permitting-first-south-dakota-critical-minerals-project-added-to-fast-41-302543274.html

SOURCE enCore Energy Corp.

HAIFA, Israel
, Sept. 2, 2025 /PRNewswire/ — ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) (“ZIM” or the “Company”), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place September 9, 2025, as previously announced by the Company on August 20, 2025 (the “Dividend”), the previously obtained tax ruling from the Israeli Tax Authority (“ITA”) on tax withholding procedures relating to the payment of the Dividend to the Company’s shareholders (the “Ruling”) shall apply.

As a result of the Ruling, certain shareholders of the Company (“Shareholders”) may be eligible to a reduced Israeli withholding tax rate with respect to their share of this Dividend, in comparison to the generally applicable withholding tax rate (the “Reduced Withholding Tax Rate”), under certain terms and conditions as set forth below.

The description provided below is not intended to constitute a complete analysis of withholding tax rate procedures relating to the distribution of the Dividend, nor does it address the actual tax liability of any of the Shareholders, but merely relates to the Israeli withholding tax procedures relating to the distribution of the Dividend. Other than the Dividend previously declared by the Company to be paid on September 9, 2025, there is no guarantee the Company will declare additional dividends in the future.

Shareholders are advised to consult their own tax and financial advisors concerning the tax consequences of each particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. For the avoidance of doubt, the Agent

IBI Trust Management
 (whose information is provided below) has been retained by ZIM for the purpose of coordinating certain procedures relating to the Ruling, and it is NOT intended that the Agent will provide any tax advice to any of the Shareholders, who are encouraged to consult their own tax and financial advisors.

Forms required to be submitted to the Agent in connection with the Ruling as described below are available in the following

link

 (the full link appears below, under the Agent’s contact information), and can also be found on the Company’s website

here

.

Background

On August 20, 2025, ZIM announced a dividend payment of $0.06 per ordinary share (approximately $7 million), to be paid to holders of ordinary shares as of September 2, 2025. Payment of the Dividend is expected to be made on September 9, 2025 (the “Payment Date”).

General Withholding Tax Treatment under Israeli Law

As set out in the Company’s Annual Report on Form 20-F filed with the Commission on March 12, 2025, with respect to dividends sourced from regular earnings, under the Israeli Tax Ordinance and regulations issued under the Israeli Tax Ordinance (collectively, “ITO”), the current Israeli rate of withholding tax on dividends paid by an Israeli company is 30% for distributions to a “substantial shareholder” (in general, being someone who holds, directly or indirectly, by himself or together with others, at least 10% of one or more of the means of control in the company) and 25% with respect to distributions to all other holders of Ordinary Shares (“Withholding Tax”). Notwithstanding the foregoing, as a result of the Ruling and subject to its terms and conditions, certain Shareholders, both Israeli and non-Israeli, may be eligible to a reduced Israeli withholding tax rate on their share of this dividend distribution, in comparison to the generally applicable withholding tax rate described above, (the “Reduced Withholding Tax Rate”), under certain terms and conditions as set forth below.

Summary of the Main Terms of the Ruling

The following is a summary of some of the key terms of the Ruling. It is emphasized that the description below does not purport to exhaust all the terms and conditions included in the Ruling and is not a complete translation of the Ruling. In order to enjoy the Reduced Withholding Tax Rate, Shareholders must comply with all the terms of the Ruling, a copy of which in the Hebrew language as well as an unofficial non-binding English translation thereof can be obtained free of charge by email by approaching the Agent (as defined below) at the contact details provided below.

1. On the Payment Date the Company will withhold 25% of the Dividend amount and will remit the tax amount to the Agent, to be handled by the Agent in accordance with the terms and conditions of the Ruling.
2. The remaining 75% of the Dividend amount will be remitted by the Company to its transfer agent, Equiniti Trust Company, LLC, which will transfer the said amount to the Shareholders (including through brokers who hold in brokerage accounts ZIM shares on behalf of Shareholders).
3. A Shareholder who is a resident of a country with which Israel has a tax treaty (“Treaty State”) (based on a declaration to be provided by such Shareholder) and is the beneficial owner of the Dividend, may apply to the Agent requesting a Reduced Tax Withholding Rate. Such application must be received by the Agent between the Payment Date and October 8, 2025 (the “Change of Rate Period”). The eligibility for a reduced tax rate will be evaluated by the Agent in accordance with Israeli tax laws and any applicable treaties, and therefore there is no guarantee that the applicant shareholder will be eligible for a tax refund.
4. A Shareholder who declared that he or she is a resident of a Treaty State and is the beneficial owner of the Dividend may apply to the Agent during the Change of Rate Period only (subject to complying with all the documentation requirements detailed below) requesting the receipt of the monetary difference between the tax amount remitted to the Agent (at a rate of 25%) and the amount represented by the withholding tax rate set forth in the tax treaty between Israel and such Treaty State or by the limited withholding tax rate applicable to such dividend payment under the ITO, to the extent applicable.
5. A Shareholder who did not declare that it, he or she is a resident of a Treaty State and is the beneficial owner of the Dividend, may apply to the Agent during the Change of Rate Period only (subject to complying with all the documentation requirements detailed below) requesting the receipt of the monetary difference between the tax amount remitted to the Agent (at a rate of 25%) and the amount represented by the withholding tax rate applicable to such dividend payment under the ITO or by the limited withholding tax rate applicable to such dividend payment under the ITO, to the extent applicable.
6. Any Shareholder who claims to be entitled to a Reduced Tax Withholding Rate in accordance with the foregoing, will be required to provide the Agent with all relevant documentation as detailed in the Ruling and the forms available in the following 
   
   link
   
   , on no later than October 8, 2025 (the end of Change of Rate Period), including but not limited to, bank account details to which the dividend payment should be transferred, number of ZIM shares owned by the Shareholder in such account, identification document, and confirmation of residence for the tax year 2025 issued by the taxing authority of the state of tax residence.
7. In addition to the foregoing, the Shareholder will provide a written declaration in the form annexed to this announcement which will include declarations as to the following: (i)  the Shareholder’s tax residence for the tax year 2025, (ii) the Shareholder’s beneficial ownership of the dividend, (iii) the investment in ZIM shares has not been made through a permanent establishment in Israel, (iv) the holding of ZIM shares is made for the Shareholder’s own account and not for the account of others, and (v) the payment will not be made to a permanent establishment of the Shareholder outside of the Shareholder’s tax residence.
8. A non-Israeli corporate Shareholder (excluding a Shareholder covered by section 9 below) that requests a Reduced Tax Withholding Rate, will also need to provide the Agent with its updated shareholders register as of September 2, 2025, and a statement confirming that more than 75% of its shareholders, directly or indirectly, are individuals of its state of residence for the tax year 2025.
9. A publicly traded non-Israeli corporate Shareholder whose shares are traded on a stock market outside of Israel and is a resident of a Treaty State, or a direct or indirect subsidiary of such Shareholder, will also provide the Agent with a declaration that it is a resident of such Treaty State or another non-Israeli state for the tax year 2025, as applicable.
10. An Israeli corporate Shareholder which is entitled to a Reduced Tax Withholding Rate (including an exemption from withholding tax at source), will be able to apply to the Agent no later than October 8, 2025, (the end of the Change of Rate Period) and enclose an applicable valid ITA issued certificate setting forth a Reduced Tax Withholding Rate or an exemption from withholding tax. In addition, such Shareholder will enclose its certificate of incorporation and all other documents required as set forth above, mutatis mutandis as requested by the Agent.
11. The Agent is entitled to request from the Shareholders applying for a Reduced Tax Withholding Rate additional documents in its discretion insofar as they are required to establish the tax residence of the Shareholder or its entitlement to exemption and/or to a Reduced Tax Withholding Rate.
12. Notwithstanding the foregoing, no refund of excess tax withholding shall be affected by the Agent with respect to any Shareholder holding more than 5% of the issued share capital of the Company, or whose entitlement to dividend from the Company pursuant to the Dividend exceeds $500,000, other than in accordance with a specific approval issued by the ITA.
13. The transfer of the amounts withheld, excluding the amounts returned to the Shareholders, as aforementioned, shall be conducted by the Agent. Subject to receipt by the Agent of your required documentation, the Agent will return the amounts withheld to the Shareholders as detailed above to the account at which the dividend payment was made within 30 days from the date the amounts withheld are paid to the ITA.
14. The Ruling is aimed to address solely the issue of tax withholding procedures and should not be construed as setting the actual tax liability of any Shareholder with respect to the Dividend or otherwise.

Appointment of Israeli Tax Withholding Agent

In order to facilitate the implementation of the procedures set forth in the Ruling for the benefit of its Shareholders, the Company appointed IBI Trust Management to serve as a processing agent for the benefit of the Shareholders in connection with the distribution of the Dividend (the “Agent”). Contact information of the Agent is provided at the bottom of this announcement. We encourage you to contact the Agent if you need any clarifications in filling-in the forms required under the Ruling to obtain a Reduced Withholding Tax Rate, or if you have any questions concerning the process. Please note that the Agent will not provide any tax advice to any Shareholder, who should consult their own tax and financial advisors.

In order to be eligible to benefit from a Reduced Withholding Tax Rate, Shareholders must provide the Agent with all documentation required under the Ruling not later than October 8, 2025. The relevant forms are included in the following link.

If a Shareholder fails to provide the Agent with all the documentation required by  October 8, 2025, the Agent will not be able to attend to such Shareholder’s application and will not be able to return any amounts originally remitted on behalf of such Shareholder nor provide any confirmation of tax withholding to such a Shareholder, either in connection with the Ruling or in connection with any other tax filing by such Shareholder.

ZIM’s Agent Contact Information:
IBI Trust Management 
Tel No: +972-3-519-3896, +972-50-620-9410 
Email: [email protected] 

Link to forms:

https://form.cellosign.co/public/djE6d2Y6MzlhOTE4M2MtYmU1My00MmNjLWFhMTktYjc5NGJmYTRjOTcxOlN0YXJ0RXZlbnRfMWl1OTBscQ==

About ZIM

Founded in Israel in 1945, ZIM (NYSE: ZIM) is a leading global container liner shipping company with established operations in more than 100 countries serving approximately 33,000 customers in over 330 ports worldwide. ZIM leverages digital strategies and a commitment to ESG values to provide customers innovative seaborne transportation and logistics services and exceptional customer experience. ZIM’s differentiated global-niche strategy, based on agile fleet management and deployment, covers major trade routes with a focus on select markets where the company holds competitive advantages. Additional information about ZIM is available at www.ZIM.com.

ZIM Contacts

Media:

Avner Shats

ZIM Integrated Shipping Services Ltd.
+972-4-865-2520
[email protected]   

Investor Relations:

Elana Holzman

ZIM Integrated Shipping Services Ltd.
+972-4-865-2300
[email protected] 

Leon Berman

The IGB Group
212-477-8438
[email protected] 

Logo – https://mma.prnewswire.com/media/1933864/5184703/ZIM_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/zim-updates-on-withholding-tax-procedures-on-september-2025-cash-dividend-302543622.html

SOURCE ZIM Integrated Shipping Services Ltd.

Investment Further Enhances Evernorth’s Participation in 
Growing Market for Specialty Medicine 

BLOOMFIELD, Conn.
, Sept. 2, 2025 /PRNewswire/ — Evernorth Health Services (“Evernorth”), a subsidiary of The Cigna Group (NYSE: CI), today announced a $3.5 billion investment in Shields Health Solutions (“Shields” or the “Company”), a leading specialty pharmacy management company. Evernorth’s investment coincides with Shields’ establishment as a private standalone company upon its acquisition by Sycamore Partners (“Sycamore”), a leading private equity firm based in New York. This follows Sycamore’s acquisition of Walgreens Boots Alliance (“WBA”), Shields’ previous owner, which closed on August 28, 2025. Evernorth’s investment in Shields is in the form of preferred stock and is not expected to have a material impact to The Cigna Group’s previously issued 2025 adjusted EPS guidance of at least $29.60.

“Demand for specialty medications continues to grow at an accelerated pace, and Evernorth is uniquely positioned to serve the rapidly expanding number of individuals living with complex and chronic conditions and the doctors who care for them,” said David M. Cordani, Chairman and Chief Executive Officer, The Cigna Group. “Investing in Shields aligns with our commitment to delivering exceptional care across health care settings – from home to physician’s office or clinic, to hospital.”

Shields helps hospitals and health systems develop and manage their own specialty pharmacies. Shields partners with more than 80 health systems comprised of more than 1,000 hospitals and clinics across nearly all 50 states.

Today, Evernorth supports patients living with specialty conditions and the providers who care for them through its direct-to-patient pharmacies, complex medication distributor, inventory management technology, home and ambulatory infusion services and more. Investing in Shields allows Evernorth to seek more opportunities to support patients and providers and enhance continuity of care across specialty health care settings. It also provides optionality for additional investment in Shields over time.

Michael Ham, Shields’ Chief Executive Officer, said, “Our team at Shields has been proud to deliver exceptional clinical, financial and operational outcomes for our health system partners and their patients served through our differentiated care model. Both Sycamore’s acquisition of Shields, and Evernorth’s support for the transaction, demonstrate clear validation of our successful health system-focused specialty pharmacy strategy and patient-focused care model.”

“We are pleased to have worked with Evernorth on this investment as Sycamore establishes Shields as a private standalone company,” said Stefan Kaluzny, Managing Director of Sycamore. “The Shields team and Evernorth share an unwavering commitment to patient care and we are proud to support Shields on its next phase of growth.”

Greenhill, an affiliate of Mizuho, is acting as the sole financial advisor to Evernorth during this transaction. Wachtell, Lipton, Rosen & Katz is serving as corporate legal counsel and Holland & Knight LLP is serving as regulatory counsel.

Cautionary Note Regarding Forward-Looking Statements

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements regarding The Cigna Group’s projected adjusted income from operations outlook for 2025 on a per share basis, the anticipated benefits of the investment, expected demand for specialty medications and our ability to meet that demand, potential future opportunities and additional investments, and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in The Cigna Group’s most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

About Evernorth Health Services

Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com.

About Shields Health Solutions

Shields Health Solutions (Shields) is the premier specialty pharmacy accelerator in the country. The Shields Performance Platform, an integrated set of solutions, services and technology, is intentionally designed to elevate payer and drug access for specialty pharmacies, elevate health outcomes for complex patients, and elevate growth throughout the entire health system. As the foremost experts in the health system specialty pharmacy industry, Shields has a proven track record of success including access to over 80 percent of all limited distribution drugs (LDDs) and most (health insurance) payers in the nation; and a clinical model proven to lower total cost of care by 13%. In partnership with nearly 80 health systems across the country through national-scale collaboration, Shields has a vested interest in delivering measurable clinical and financial results for health systems. For more, follow us on social media, @ShieldsRX, LinkedIn, Facebook, and YouTube. Shields Health Solutions employs more than 2,000 people across the country.

About Sycamore Partners

Sycamore Partners is a private equity firm based in New York. The firm specializes in consumer, distribution and retail-related investments and partners with management teams to improve the operating profitability and strategic value of their business. With approximately $11 billion in aggregate committed capital raised since its inception in 2011, Sycamore Partners’ investors include leading endowments, financial institutions, family offices, pension plans and sovereign wealth funds. For more information on Sycamore Partners, visit www.sycamorepartners.com.

Contacts

Evernorth Health Services 

Justine Sessions

[email protected] 

Shields Health Solutions 

Crystal Chuckel, Chief Corporate Affairs Officer
[email protected]

Ruth Pachman or Daniel Hoadley
Kekst CNC
[email protected] / [email protected] 

Sycamore Partners

Michael Freitag, Zach Genirs, Abigail South
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-health-services-announces-investment-in-shields-health-solutions-302543676.html

SOURCE The Cigna Group

JACKSON, Mich.
, Sept. 2, 2025 /PRNewswire/ — Consumers Energy is increasing efforts to enhance the reliability of electric service in the final stretch of the year. Crews and contractors are already working in neighborhoods during extended hours — including evenings, and weekends — as part of an accelerated maintenance and infrastructure improvement program.

“Our customers count on us for safe, reliable service year-round,” said Chris Fultz, Consumers Energy’s vice president of low voltage distribution. “As we enter the final months of the year, we’re extending work hours so we can complete critical reliability projects ahead of cold temperatures.”

To support this ramp-up, Consumers Energy is also increasing resources and working hours, allowing more hands on deck to complete essential upgrades faster and more efficiently.

The work includes:

• Upgrading poles, lines, and transformers.
• Proactive tree trimming near power lines.
• Replacing equipment nearing the end of its service life.
• Installing smart grid technology to reduce outage times.

While crews are on site, traffic may be briefly affected and residents may hear work-related noise outside of typical business hours. All workers and contractors will have clearly marked vehicles and identification.

The expanded schedule will allow more projects to be completed in less time, helping to prevent outages and service disruptions during the harshest months of the year.

“We appreciate our customers’ patience as we work to strengthen the system,” said Fultz. “Completing this work now ensures we’re well-positioned to deliver reliable service through the end of the year and beyond.”

In 2024, Consumers Energy carried out over 1,350 major upgrades and cleared trees, limbs and branches along 7,000 miles of electric lines last year. With the increased efforts in the last part of the year, we are on track to surpass last year’s numbers.

Consumers Energy is Michigan’s largest energy provider, providing natural gas and/or electricity to 6.8 million of the state’s 10 million residents in all 68 Lower Peninsula counties. Consumers Energy knows job number one is to keep the lights on for customers. We are committed to delivering reliable, flexible, and affordable energy to our customers 24/7.  

For more information about Consumers Energy, go to
ConsumersEnergy.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/consumers-energy-crews-working-extended-hours-to-strengthen-reliability-302542400.html

SOURCE Consumers Energy

Invests $45.0 Million in Recapitalization of a Specialty Aircraft Distributor

HOUSTON
, Sept. 2, 2025 /PRNewswire/ — Main Street Capital Corporation (NYSE: MAIN) (“Main Street”) is pleased to announce that it recently completed a new portfolio investment totaling $45.0 million to facilitate the minority recapitalization of a leading specialty aircraft distributor (the “Company”). Main Street partnered with the Company’s Chief Executive Officer, who was also the Company’s sole owner, to facilitate the transaction, with Main Street’s investment including a combination of first lien, senior secured debt and a direct minority equity investment.

Founded over 30 years ago and headquartered in the Southeastern U.S., the Company is an industry-leading specialized aircraft distributor, parts supplier and maintenance provider. The Company serves a diverse customer base, primarily in North and South America.

ABOUT MAIN STREET CAPITAL CORPORATION
Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides customized long-term debt and equity capital solutions to lower middle market companies and debt capital to private companies owned by or in the process of being acquired by a private equity fund. Main Street’s portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides customized “one-stop” debt and equity financing solutions within its lower middle market investment strategy. Main Street seeks to partner with private equity fund sponsors and primarily invests in secured debt investments in its private loan investment strategy. Main Street’s lower middle market portfolio companies generally have annual revenues between $10 million and $150 million. Main Street’s private loan portfolio companies generally have annual revenues between $25 million and $500 million.

Main Street, through its wholly-owned portfolio company MSC Adviser I, LLC (“MSC Adviser”), also maintains an asset management business through which it manages investments for external parties. MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940, as amended.

Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, [email protected]
Ryan R. Nelson, CFO, [email protected]
713-350-6000

Dennard Lascar Investor Relations
Ken Dennard | [email protected]
Zach Vaughan | [email protected]
713-529-6600

 

View original content:https://www.prnewswire.com/news-releases/main-street-announces-new-portfolio-investment-302542608.html

SOURCE Main Street Capital Corporation

LA JOLLA, Calif.
, Sept. 2, 2025 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:30 p.m. ET.

A live webcast of the presentation can be accessed in the “IR Events and Presentations” section of CalciMedica’s IR website. A replay of the webcast will be archived on the Company’s website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica’s proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visit www.calcimedica.com.

Contact Information

Kevin Murphy


[email protected]

(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html

SOURCE CalciMedica, Inc.